Por Renan Filho · 2026-09-24A senior official from the World Health Organization (WHO) has stated that male contraceptive options – including oral pills and injectable hormones – could be available in pharmacies across the United Kingdom within the next three to five years. The statement, made during a press briefing at the WHO’s Geneva headquarters, has reignited debate over the role of government regulation, pharmaceutical incentives, and individual liberty in matters of reproductive health.
According to Dr. Mario Festin, a scientist in the WHO’s Department of Sexual and Reproductive Health, several promising candidates are currently in the late stages of clinical trials. “We are seeing real progress in the development of male contraceptives that are both effective and reversible,” he said. “If the current trials continue to show positive results, we could see products submitted for regulatory approval within two to three years, and on the market in three to five.”
Currently, the only widely available male contraceptive methods in the UK are condoms and vasectomy. Both have significant limitations: condoms have a typical-use failure rate of around 13%, according to NHS data, while vasectomy – although highly effective – is considered permanent and difficult to reverse. The prospect of a temporary hormonal contraceptive for men, similar to the combined oral contraceptive pill for women, has been a goal of medical researchers for decades.
**Why This Matters**
The arrival of a male contraceptive pill or injection would represent a profound shift in the dynamics of reproductive responsibility. For decades, the burden of contraception has fallen overwhelmingly on women, who have shouldered the side effects, costs, and logistical challenges of hormonal birth control, intrauterine devices, and implants. In 2023, women in the UK spent an estimated £150 million on contraceptive prescriptions and over-the-counter products, according to figures from the Family Planning Association. A male alternative could rebalance that burden, offering men greater agency and freeing women from reliance on often-invasive methods.
From a public health perspective, unplanned pregnancy remains a significant issue. The British Pregnancy Advisory Service (BPAS) reported that in 2024, approximately 45% of pregnancies in England and Wales were unintended. Improved male contraceptive options could reduce that figure, lowering demand for abortion services and reducing the emotional and financial strain on families and the NHS.
**FORTIS Analysis: Free Market vs. Bureaucratic Delays**
The WHO’s timeline, while cautiously optimistic, highlights a recurring tension in pharmaceutical development. The free market has traditionally underinvested in male contraception because of perceived low demand and the high cost of clinical trials. Large pharmaceutical companies, which can spend upwards of £1 billion bringing a new drug to market, have been reluctant to risk that capital on a product whose consumer base is uncertain. The result has been a market failure: women have dozens of contraceptive options, men have two.
Yet recent years have seen a surge in small biotech firms and academic spin-offs taking up the challenge. Organisations such as the Male Contraceptive Initiative (non-profit) and companies like YourChoice Therapeutics (US) and Contraline (Australia) are developing non-hormonal and hormonal alternatives. Their progress suggests that when regulatory barriers are lowered and intellectual property protections are clear, innovation can flourish. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has historically been quicker than the European Medicines Agency in approving innovative therapies, a fact that could give British men earlier access to these products.
However, the FORTIS editorial line is to remain sceptical of state-led optimism. The WHO, a United Nations agency, has a track record of making ambitious predictions that are later delayed by bureaucracy, funding gaps, and political interference. The same agency that famously predicted in 2019 that a universal coronavirus vaccine would be ready within 18 months – a promise that did not materialise – now offers a three-to-five-year timeline for male contraceptives. This does not mean the prediction is false, but it serves as a reminder that government and intergovernmental bodies do not operate under market discipline. Their timelines are not binding; they are aspirations.
Moreover, the regulatory pathway for a new hormonal contraceptive for men is fraught with uncertainty. The MHRA and the US Food and Drug Administration (FDA) will demand rigorous evidence of long-term safety, particularly regarding fertility recovery after discontinuation. In 2016, a study of a hormonal male contraceptive injection was halted early because of side effects such as depression and acne. Since then, researchers have refined formulations, but the safety bar remains high. If regulators demand decade-long follow-up studies, the three-to-five-year window could easily stretch to ten or fifteen years.
**Counterpoint: The Case for Caution**
Not everyone is convinced that male contraceptives are imminent or desirable. Some feminist groups have expressed concern that men may not adhere to a daily pill regimen, leading to higher failure rates and unintended pregnancies. Others worry that the male pill could be used coercively by partners, though such concerns apply equally to female contraception. From a medical standpoint, endocrinologists note that suppressing sperm production is biologically more complex than suppressing ovulation, and that the long-term hormonal effects on male health remain understudied.
Economically, the NHS may face a difficult calculation. If male contraceptives are priced similarly to female oral contraceptives – typically around £20–£30 per month – the cost to the taxpayer could be substantial if uptake is high. Conversely, the savings from reduced unintended pregnancies and lower abortion rates could offset those costs in the long run. A proper cost-benefit analysis, conducted by independent auditors rather than by the government, would be essential before any public subsidy is considered.
**Q: Will the male contraceptive pill be available on the NHS?** A: That will depend on guidance from the National Institute for Health and Care Excellence (NICE). If the product is deemed clinically and cost-effective, it will likely be added to the NHS prescription list. However, the timeline for such an assessment typically takes one to two years after marketing authorisation. Patients may initially have to pay for private prescriptions or use over-the-counter options if they are reclassified as pharmacy medicines.
**Q: Are there any non-hormonal male contraceptives in development?** A: Yes. Several non-hormonal approaches are in preclinical or early clinical stages, including gels that block the vas deferens, ultrasound-based treatments, and oral compounds that interfere with sperm motility without affecting testosterone levels. These alternatives may avoid some of the hormonal side effects seen in earlier trials, but they are further behind in development – likely a decade away from market availability.